Novartis

Novartis, a Pharmaceutical Preparation Manufacturing company headquartered in Switzerland, reported total carbon emissions of 4,377,100,000 kg CO2e in 2025. This figure comprises 192,300,000 kg CO2e from Scope 1, 14,900,000 kg CO2e (market-based) from Scope 2, and 4,169,900,000 kg CO2e from Scope 3.

In 2024, Novartis's total emissions were approximately 4,522,600,000 kg CO2e. This included 210,600,000 kg CO2e from Scope 1, 29,800,000 kg CO2e (market-based) from Scope 2, and 4,282,200,000 kg CO2e from Scope 3. Comparing these figures, the company saw a decrease in total emissions between 2024 and 2025.

In 2023, the company's total emissions were about 4,868,900,000 kg CO2e, with 251,100,000 kg CO2e from Scope 1, 44,100,000 kg CO2e (market-based) from Scope 2, and 4,573,700,000 kg CO2e from Scope 3.

Novartis has set ambitious climate commitments, with Science Based Targets initiative (SBTi) approved targets. The company aims to achieve net-zero greenhouse gas emissions across its value chain by 2040, based on a 2022 baseline. Near-term targets include reducing absolute Scope 1 and 2 GHG emissions by 90% by 2030 from a 2022 base year, and absolute Scope 3 GHG emissions by 42% within the same timeframe. Long-term targets aim for a 90% absolute reduction in Scope 1 and 2 emissions from 2030 through to 2040 from a 2022 baseline, and a 90% reduction in absolute Scope 3 GHG emissions by 2040 from a 2022 base year.

Additionally, Novartis is committed to becoming carbon neutral in its own operations (Scope 1 and 2) by 2025 and carbon neutral across its entire value chain by 2030. As of 2023, the company reported a 63% reduction in Scope 1 and 2 emissions (from energy) compared to its 2016 baseline. Novartis is also a signatory to The Climate Pledge, committing to net-zero carbon by 2040.